User login
Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who had an isolated brain metastasis as their first metastatic event reported worse survival outcomes than those with concurrent progressive or stable/responding extracranial disease (ECD).
Major finding: Patients with isolated brain relapse or no evidence of ECD (28.4 months; P = .0028) reported worse overall survival from metastatic diagnosis to death than patients with concurrent progressive ECD (48.8 months) or stable/responding disease (71.5 months).
Study details: Findings are from a retrospective analysis including 126 patients with HER2+ BC, brain metastasis, and known ECD status.
Disclosures: This study was funded by the Duke University Department of Medicine and other sources. Some authors declared receiving royalties or serving as consultants at various sources.
Source: Noteware L et al. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. Breast Cancer Res Treat. 2022 (Nov 20). Doi: 10.1007/s10549-022-06799-7
Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who had an isolated brain metastasis as their first metastatic event reported worse survival outcomes than those with concurrent progressive or stable/responding extracranial disease (ECD).
Major finding: Patients with isolated brain relapse or no evidence of ECD (28.4 months; P = .0028) reported worse overall survival from metastatic diagnosis to death than patients with concurrent progressive ECD (48.8 months) or stable/responding disease (71.5 months).
Study details: Findings are from a retrospective analysis including 126 patients with HER2+ BC, brain metastasis, and known ECD status.
Disclosures: This study was funded by the Duke University Department of Medicine and other sources. Some authors declared receiving royalties or serving as consultants at various sources.
Source: Noteware L et al. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. Breast Cancer Res Treat. 2022 (Nov 20). Doi: 10.1007/s10549-022-06799-7
Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who had an isolated brain metastasis as their first metastatic event reported worse survival outcomes than those with concurrent progressive or stable/responding extracranial disease (ECD).
Major finding: Patients with isolated brain relapse or no evidence of ECD (28.4 months; P = .0028) reported worse overall survival from metastatic diagnosis to death than patients with concurrent progressive ECD (48.8 months) or stable/responding disease (71.5 months).
Study details: Findings are from a retrospective analysis including 126 patients with HER2+ BC, brain metastasis, and known ECD status.
Disclosures: This study was funded by the Duke University Department of Medicine and other sources. Some authors declared receiving royalties or serving as consultants at various sources.
Source: Noteware L et al. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. Breast Cancer Res Treat. 2022 (Nov 20). Doi: 10.1007/s10549-022-06799-7